European Cannabis Regulations by Country: The 2026 Business Guide

The EU-Level Context: What Brussels Actually Controls

A common misconception among operators entering Europe is that EU membership creates a de facto unified cannabis market. It does not. Cannabis regulation — whether medical, adult-use or hemp-derived — falls within the competence of member states under the subsidiarity principle. The EU has not sought to create a common cannabis framework and shows no signs of doing so in the near term.

The EU's influence on cannabis markets operates through three indirect channels. First, pharmaceutical regulation: where cannabis is prescribed as a medicine, it is subject to the European Medicines Agency's frameworks (for centrally authorised products) or national competent authority approval, and must meet EU Good Manufacturing Practice (EU-GMP) standards under Directive 2001/83/EC. Second, Novel Foods regulation: CBD and hemp-derived food ingredients are classified as Novel Foods under EU Regulation 2015/2283, requiring pre-market safety assessment by the European Food Safety Authority (EFSA). Third, international narcotics obligations: all EU member states are signatories to the 1961 Single Convention on Narcotic Drugs, which constrains the form that commercial adult-use frameworks can take.

The practical consequence for operators is that market entry into Europe requires a country-by-country regulatory analysis — there is no single access point. A product approved in Germany does not have automatic authorisation in France or Italy. A cultivation licence granted in Portugal conveys no rights in the Netherlands. Each market is a discrete regulatory exercise.

The European Medicines Agency and Cannabis

The European Medicines Agency (EMA) has not granted centralised marketing authorisation to any cannabis-based medicinal product as of 2026. Sativex (nabiximols) holds national authorisations in several member states but not EMA central authorisation. This means that CBMPs entering European markets must navigate national regulatory pathways in each target jurisdiction — a resource-intensive process that favours well-capitalised operators.

The EMA has, however, issued guidance on CBMP development, and its Committee for Medicinal Products for Human Use (CHMP) has been active in reviewing cannabinoid medicines. For operators with novel CBMP formulations targeting multiple EU markets simultaneously, the EMA central procedure remains a theoretically available pathway — though no operator has successfully navigated it to date for a cannabis product.

Country-by-Country Regulatory Comparison

The table below provides a reference overview of the regulatory status of cannabis across 11 key European markets. Data reflects the position as of April 2026. Operators should conduct jurisdiction-specific due diligence before making market entry decisions.

Medical Cannabis Regulatory Frameworks

Across Europe, medical cannabis programmes fall into three broad categories distinguished by the depth of prescribing access, reimbursement availability and product authorisation pathways.

Full Prescription Access Markets

Germany, the Netherlands, France (since March 2024), Italy and Denmark constitute the group of markets where prescription access is established and patient populations are measurable at scale. Germany is the clear outlier in terms of market size: the combination of mandatory GKV reimbursement, open prescribing (any doctor, any indication, since April 2024) and a population of 84 million has produced a market that dwarfs all others. Italy's programme, whilst legally established, is constrained by limited domestic production capacity and the dominant role of the IMFF (Stabilimento Chimico Farmaceutico Militare) as the primary supply point.

The Netherlands occupies a unique position as the continent's oldest programme (dating to 2000 through the Bureau voor Medicinale Cannabis, BMC) and as a state production monopoly that also exports. Bedrocan's standardised genetic varieties — Bedrocan, Bedrobinol, Bediol, Bedica and Bedrolite — have become de facto reference products in European pharmacopoeia discussions.

Restricted Access Markets: The UK

The UK's medical cannabis framework, established in November 2018 following Schedule 2 rescheduling of cannabis-based products, is technically permissive but practically restrictive on the NHS. Fewer than 20,000 NHS patients have active prescriptions, constrained by prescriber reluctance, formulary restrictions and clinical guidance that remains cautious. The private clinic sector has substantially filled the gap: estimates suggest approximately 100,000 patients access cannabis through private prescriptions, with clinics including Sapphire Medical Clinics, Mamedica and others processing significant prescription volumes.

Project Twenty21, run by Drug Science, produced the largest real-world evidence dataset on medical cannabis in Europe — over 3,000 patients, 52 conditions — and has been influential in building the prescriber evidence base. The MHRA (gov.uk/MHRA) governs both the licensing of CBMPs and the import pathway for unlicensed products; operators supplying the UK market require MHRA manufacturing authorisations in addition to any EU-GMP certification held.

GACP vs EU-GMP: What Operators Need to Know

For any business supplying cannabis products into European pharmaceutical channels, mastery of the distinction between GACP and EU-GMP is non-negotiable. Confusing the two — or assuming one encompasses the other — is a common and costly mistake made by operators entering European markets from North America or emerging markets.

Good Agricultural and Collection Practice (GACP)

GACP is the quality standard governing the cultivation and primary processing of medicinal plants. For cannabis, it covers seed and variety selection, soil management, irrigation, pest and disease control, harvesting conditions, drying, storage and the documentation of all practices. Compliance with GACP is assessed by national competent authorities and, in some cases, via third-party certification bodies. GACP is effectively the minimum quality threshold for cannabis entering European pharmaceutical supply chains at the raw material stage.

Critically, GACP certification alone does not permit a cultivator to supply finished pharmaceutical products. Cannabis flower produced under GACP must be processed, tested and released under EU-GMP conditions before it can enter prescription channels.

EU Good Manufacturing Practice (EU-GMP)

EU-GMP is the manufacturing quality standard mandated under Directive 2001/83/EC for all medicinal products sold in the European Economic Area. For cannabis manufacturers — extractors, formulators, packagers and importers — EU-GMP certification from the national competent authority of an EEA member state (or, for UK supply, MHRA manufacturing authorisation) is mandatory. EU-GMP inspections are thorough and expensive; certification timelines of 12–24 months from application to approval are common.

The practical implication for supply chain strategy: operators in third countries (Canada, Australia, Colombia, Uruguay) seeking to supply European markets must obtain EU-GMP certification either from a member state authority willing to conduct overseas inspections — Germany's BfArM, Portugal's Infarmed and Denmark's DKMA have all conducted international EU-GMP inspections — or via a licensed EU-based site that further processes the product.

The Novel Foods Issue: CBD Across the EU

The Novel Foods classification of CBD by the European Commission, confirmed in 2019 and maintained through subsequent EFSA reviews, fundamentally shapes the CBD product market in Europe. Under EU Regulation 2015/2283, any food or food supplement containing CBD requires pre-market authorisation — a process involving a full safety dossier submission to the European Food Safety Authority, scientific assessment and, if positive, inclusion in the EU Novel Foods Catalogue.

As of early 2026, the first CBD Novel Foods authorisation applications are working through the EFSA pipeline, with outcomes expected in the near term. The commercial reality has been that many CBD products have been sold across Europe in a regulatory grey zone — tolerated in some markets, actively enforced against in others. The Netherlands, France and Germany have all taken enforcement action against non-compliant CBD food products at various points.

For operators in the CBD sector, the near-term strategic imperative is clear: secure Novel Foods authorisation or partner with an authorised supplier. The regulatory risk of operating without authorisation is increasing as national authorities become more active in enforcement, and the reputational cost of a product withdrawal is substantial in a B2B context.

Cross-Border Supply and the Single Convention

Moving cannabis products across European borders — even within the EU — requires compliance with the 1961 Single Convention on Narcotic Drugs and its implementing national legislation. Cannabis remains a Schedule I and Schedule IV narcotic under the Single Convention, meaning that export and import of cannabis products requires narcotics transit permits issued by the relevant national competent authorities in both exporting and importing countries.

For operators moving medical cannabis from Portugal to Germany, or from the Netherlands to the UK, this means obtaining import and export licences from Infarmed/BfArM and IGJ/MHRA respectively for each consignment. These are not one-time licences; they are consignment-specific in most jurisdictions. The administrative burden is material, particularly for operators managing multi-market supply chains.

Germany's position as Europe's largest import market means that any cultivation or manufacturing operation in Portugal, the Netherlands, Denmark or North Macedonia that wishes to access the German market must have the narcotics import/export infrastructure in place before first shipment. BfArM's narcotics licensing team publishes guidance on the BfArM website, and the Bundesgesundheitsministerium provides an overarching policy framework document.

Post-Brexit UK: Regulatory Divergence

The UK's departure from the EU in 2020 created a distinct regulatory jurisdiction that operators must treat as entirely separate from EU market access. EU-GMP certification from an EEA national authority does not provide automatic equivalence for UK supply — operators must hold MHRA manufacturing authorisation for UK import and supply. This creates a genuine duplication of compliance costs for operators serving both EU and UK markets.

On the medicines pathway side, the MHRA's Unfettered Access provisions allow certain products approved in Great Britain to access Northern Ireland, but the practical relevance for cannabis operators is limited. The UK government has indicated it will develop its own CBMP prescribing and authorisation framework independently of EMA processes, and the MHRA has begun publishing updated guidance specific to cannabis-derived medicinal products.

CBD in the UK is regulated as a Novel Food by the Food Standards Agency (FSA), which maintains a validated products list. The FSA process is a separate national procedure from the EFSA EU Novel Foods pathway, and a product validated by the FSA is not automatically authorised for EU sale, and vice versa. For operators selling in both markets, dual regulatory submissions are required.

Key Regulatory Developments to Watch in 2026